CLOVIS ONCOLOGY INC
CLOVIS ONCOLOGY INC
Aktie · US1894641000 · CLVS · A1JPJY (XNAS)
Übersicht Finanzkennzahlen
Kein Kurs
n/a

Performance

Heute Woche Monat 3 Monate 6 Monate 1 Jahr 5 Jahre
- - - - 0,00 % 0,00 % -98,80 %

Firmenprofil zu CLOVIS ONCOLOGY INC Aktie

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado. On December 11, 2022, Clovis Oncology, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Investierte Fonds

Folgende Fonds haben in investiert: CLOVIS ONCOLOGY INC investiert:

Fonds
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. in Mio
16,25
Anteil (%)
0,04 %

Unternehmensdaten

Name CLOVIS ONCOLOGY INC
Firma Clovis Oncology, Inc.
Symbol CLVS
Website https://www.clovisoncology.com
Heimatbörse XNAS NASDAQ
WKN A1JPJY
ISIN US1894641000
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Mr. Patrick Mahaffy
Land Vereinigte Staaten von Amerika
Währung USD
Mitarbeiter 0,4 T
Adresse 5500 Flatiron Pkwy Unit 100, 80301 Boulder
IPO Datum 2011-11-16

Ticker Symbole

Name Symbol
NASDAQ CLVS

Weitere Aktien

Investoren die CLOVIS ONCOLOGY INC die halten, haben auch folgende Aktien im Depot:
ALLIANZ FDS JAPAN A (EUR)
ALLIANZ FDS JAPAN A (EUR) Fonds
AMGEN INC
AMGEN INC Aktie
AUTODESK INC
AUTODESK INC Aktie
AUTOMATIC DATA PROCESSING INC
AUTOMATIC DATA PROCESSING INC Aktie
BANCFIRSTCORP - 7.2% CUMULATIVE TRUST PREFERRED SECURITIES
BANCFIRSTCORP - 7.2% CUMULATIVE TRUST PREFERRED SECURITIES Fonds
CISCO SYSTEMS INC
CISCO SYSTEMS INC Aktie
COSTCO WHOLESALE CORP
COSTCO WHOLESALE CORP Aktie
HONEYWELL INTERNATIONAL INC
HONEYWELL INTERNATIONAL INC Aktie
INTEL CORP
INTEL CORP Aktie
MICROSOFT CORP
MICROSOFT CORP Aktie
NORTHPOINTE BANCS. O.N.
NORTHPOINTE BANCS. O.N. Aktie
QIAGEN NV (alt)
QIAGEN NV (alt) Aktie
Vanguard Financials Index Fund
Vanguard Financials Index Fund Fonds
WALGREENS BOOTS ALLIANCE INC
WALGREENS BOOTS ALLIANCE INC Aktie
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025